MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (MPNs).The Shorespan-007 study is recruiting patients with ET – which causes high levels of platelets to form in the blood – who have not been previously treated with cytoreductive therapy to reduce their numbers.

MSD启动了一项新的口服LSD1抑制剂bomedemstat治疗原发性血小板增多症（ET）的3期临床试验，ET是一种罕见的血癌，被称为骨髓增生性肿瘤（MPN）。Shorespan-007研究正在招募ET患者，ET导致血液中形成高水平的血小板，这些患者以前没有接受过细胞减灭治疗以减少其数量。

It will be compared to hydroxyurea, the standard first-line cytoreductive therapy.ET is the most common type of MPN and puts patients at risk of serious complications including stroke, heart attack or pulmonary embolism. The disease, which is more common in women than men and in older individuals, is estimated to affect fewer than 200,000 people in the US.LSD1 is thought to play a role in the maturation of blood cells in the bone marrow and acts as a driver for ET and other MPNs.Bomedemstat was the main asset in MSD's $1.35 billion acquisition of Imago BioSciences which closed last year, one of a series of bolt-on deals the company has embarked upon to build its pipeline and prepare for the loss of patent protection for cancer blockbuster Keytruda (pembrolizumab) – which accounted for 40% of its pharma sales last year – in 2028.It was also part of a drive to build a franchise in haematology, and particularly in blood cancers where it has several drugs in clinical development.

它将与羟基脲（标准的一线细胞减灭疗法）进行比较。ET是最常见的MPN类型，使患者面临严重并发症的风险，包括中风，心脏病发作或肺栓塞。这种疾病在女性中比男性和老年人更常见，据估计在美国影响不到20万人。LSD1被认为在骨髓中血细胞的成熟中起作用，并作为ET和其他MPN的驱动因素。Bomedemstat是MSD斥资13.5亿美元收购Imago BioSciences的主要资产，该公司于去年完成了收购，这是该公司在2028年开始的一系列补强交易之一，旨在建设其管道，并为失去癌症大片Keytruda（pembrolizumab）的专利保护做准备。Keytruda（pembrolizumab）去年占其制药销售额的40%。这也是在血液学领域建立特许经营权的一部分，尤其是在血液癌症领域，该公司在临床开发中有多种药物。

One of those haematology drugs – Winrevair for pulmonary artery hypertension (PAH) which was acquired as part of the company's $11.5 billion takeover of Acceleron in 2021 – was approved in the EU earlier this weekMSD is already running the phase 3 Shorespan-006 trial of the drug in ET patients who have an inadequate response to or are intolerant of hydroxyurea, comparing it to a range of other alternative.

其中一种血液学药物-Winrevair治疗肺动脉高压（PAH），是该公司于2021年以115亿美元收购Acceleron的一部分收购的-于本周早些时候在欧盟获得批准。MSD已经在对羟基脲反应不足或不耐受的ET患者中进行了该药物的3期Shorespan-006试验，并将其与一系列其他替代药物进行了比较。